$48.90
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

Prestige Consumer Healthcare, Inc. engages in the marketing, sale, and distribution of pharmaceutical drugs and consumer products. The company is headquartered in Tarrytown, New York and currently employs 600 full-time employees. The company went IPO on 2005-02-10. The firm is engaged in the development, manufacturing, marketing, sales and distribution of over-the-counter (OTC) health and personal care products to mass merchandisers, drug, food, dollar, convenience, club stores and e-commerce channels in North America (the United States and Canada) and in Australia and certain other international markets. Its segments include North American OTC Healthcare and International OTC Healthcare. Its diverse portfolio of brands includes Monistat and Summer’s Eve women's health products, BC and Goody's pain relievers, Clear Eyes and TheraTears eye care products, DenTek specialty oral care products, Dramamine motion sickness treatments, Fleet enemas and glycerin suppositories, Chloraseptic and Luden's sore throat treatments and drops, Compound W wart removal products, Boudreaux’s Butt Paste diaper rash ointments, Nix lice treatment products, Debrox earwax remover, and others.
Country

US

CEO

Mr. Ronald Lombardi

IPO date

2005

Employees

890

ISIN

US74112D1019

Key stats

Open

$48.47

Volume

439.48K

Market cap

$2.30B

Prev. close

$48.48

Impl / hst vl

-

Open interest

$0.00

$48.47

Day’s Range

$49.33

$42.62

52W Range

$71.07

Valuation

77
Valuation score
Undervalued
P/E
12.07
P/S
2.11
P/B
1.22
Current ratio
3.57
Debt / Equity
0.51
ROE
10.29%
Gross margin
51.95%
Income growth
15.49%
FCF growth
-50.00

Analysts estimates

Consensus rating
Buy

The average rating from top 4 analysts indicates that stock is expected to perform in line with the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$67.32
The top 5 analysts forecasts that 12-month price may increase by 37.67%, with a low of $50.50 and a high of $78.75
$50.50
Low
$67.32
Avg
$78.75
High
Current price

Earnings

Q1 ‘26 revenue
$281.62M
Q1 ‘26 net income
$53.93M
Revenue
Net income
Previous EPS
$1.07
Estimate EPS
$1.16
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply